Pembrolizumab Improves Event-Free Survival in Early NSCLC - Oncology Nurse Advisor

For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery. For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery.

Related Keywords

San Antonio , Texas , United States , Montreal , Quebec , Canada , Jonathan David Spicer , Mcgill University , Society Of Thoracic Surgeons , Healthday News , Thoracic Surgeons , David Spicer ,